Dr. Aggarwal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave
Room M987
San Francisco, CA 94143Phone+1 415-476-1000
Education & Training
- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2010 - 2013
- University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
- Northwestern University The Feinberg School of MedicineClass of 2006
Certifications & Licensure
- CA State Medical License 2008 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jun 01
- Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer Start of enrollment: 2013 Oct 29
- Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
- Join now to see all
Publications & Presentations
PubMed
- 50 citationsAccelerating precision medicine in metastatic prostate cancer.Joaquin Mateo, Rana R. McKay, Wassim Abida, Rahul Aggarwal, Joshi J. Alumkal
Nature Cancer. 2020-11-17 - 214 citationsGenomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.David A Quigley, Ha X Dang, Shuang G Zhao, Paul Lloyd, Rahul Aggarwal
Cell. 2018-07-26 - 86 citationsErratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039))David A. Quigley, Ha X. Dang, Shuang G. Zhao, Paul Lloyd, Rahul Aggarwal
Cell. 2018-10-18
Lectures
- Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.2019 ASCO Annual Meeting - 6/1/2019
- DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant pr...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
- Breaking the Boundaries Between Radiology and Oncology: GU Oncology Profiles Thomas a. Hope, MDApril 28th, 2022
- Androgen Deprivation Therapy and SARS-CoV-2 in Men with Prostate Cancer: Findings from the University of California Health System RegistryFebruary 8th, 2021
- Xynomic Pharma to Present Long-Term Follow up Data Showing Abexinostat, Combined with Pazopanib, Has Durable Responses in Patients with Pre-Treated Kidney CancerMay 21st, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: